Lilly's Psoriasis-Obesity Combination: Compelling Biology, Exploratory Evidence, Undefined Regulatory Path

Lilly's Taltz and Zepbound Combo Shows Broad Biomarker Shifts in Psoriasis

Eli Lilly and Company announced exploratory Phase IIIb trial results demonstrating that a combination of Taltz and Zepbound significantly altered more immune and metabolic biomarkers compared to Taltz monotherapy in 274 adults with moderate-to-severe plaque psoriasis and obesity or overweight. By week 36, dual therapy shifted 482 proteins and 467 genes, versus 140 proteins and 16 genes with Taltz alone. This broader biological response was linked to greater reductions in inflammatory immune activity and enhanced Psoriasis Area and Severity Index (PASI) response, building on previously reported superior skin clearance and weight loss outcomes maintained through 52 weeks.

• The combination of Taltz and Zepbound led to a substantial shift in circulating blood proteins and gene expression, with 482 proteins and 467 genes altered by week 36, significantly more than the 140 proteins and 16 genes affected by Taltz monotherapy. These distinctions were evident as early as week 12, highlighting a broad biological impact.
• Dual therapy resulted in greater reductions in inflammatory immune activity, specifically impacting neutrophil markers, which partly contributed to an enhanced Psoriasis Area and Severity Index (PASI) response. This suggests a direct link between the observed biomarker changes and improved clinical outcomes in psoriasis.
• Earlier data from the 52-week trial had already shown that the Taltz and Zepbound combination achieved superior skin clearance (PASI 100) and at least 10% weight reduction at week 36, with these responses maintained through week 52. The safety profile of the combination was consistent with the established profiles of each individual therapy.
• Lilly emphasized that these findings support a more comprehensive approach to psoriasis care, particularly for patients also managing obesity. The observed relationship between immune and metabolic biology underscores the potential benefits of addressing both conditions concurrently, moving beyond separate treatment lenses.

Addressing the Compounded Burden of Psoriasis and Obesity

Obesity represents one of the most clinically significant and prevalent comorbidities in moderate-to-severe plaque psoriasis, with real-world cohorts reporting obesity in 39–45.5% of biologic-treated patients. The intersection of excess adiposity and chronic skin inflammation creates compounded pharmacokinetic, immunological, and cardiometabolic challenges that standard treatment algorithms have not fully resolved, driving active investigation across multiple biologic classes and weight-loss modalities.

• Obese patients with suboptimal biologic response. Higher BMI is independently associated with reduced odds of complete skin clearance across biologic classes. A systematic review and meta-analysis (n = 13,902) identified higher BMI as a negative predictor of clearance (OR 0.94, 95% CI 0.92–0.97, p < 0.001). In secukinumab-treated patients, obesity (BMI ≥ 30) was associated with an OR of 0.42 for durable response, and a lower baseline TG/HDL-C ratio emerged as an independent predictor of sustained efficacy — pointing to the need for pre-treatment metabolic stratification tools in this population.

• Biologic-experienced obese patients seeking durable clearance. Real-world data from the PSO-TARGET cohort show that brodalumab achieved PASI 100 in 48.6% of patients with obesity at week 52, with drug survival of 88.3–100% across BMI subgroups, supporting its use in bio-experienced obese patients. Similarly, bimekizumab maintained high absolute skin clearance rates regardless of advanced age or obesity over 2 years, with BMI not significantly affecting treatment persistence. Risankizumab demonstrated PASI90 and PASI100 maintained up to five years across all BMI categories, though some studies suggested enhanced early responses in non-obese patients.

• Patients requiring weight-adapted dosing strategies. Fixed-dose biologics may have reduced efficacy in patients with higher BMI, while weight-based dosing can increase the burden of drug-specific side effects. Tildrakizumab is currently the only IL-23p19 inhibitor offering two dosing options (100 mg or 200 mg) calibrated to individual patient characteristics including high disease burden and body weight, addressing an unmet need for dose individualization in obese psoriasis patients.

• Obese psoriasis patients with concomitant NAFLD/MASLD. Psoriatic patients carry a significantly elevated risk of non-alcoholic fatty liver disease (NAFLD), with one case-control study reporting a prevalence of 66.2% in psoriatic patients versus 42.3% in controls (OR = 2.6, p < 0.01), and a real-world cohort documenting hepatic steatosis in 73.6% of biologic-treated patients. Metabolic syndrome, BMI, PASI score, serum triglycerides, LDL, and age were identified as independent predictors of NAFLD in psoriasis, underscoring the need for routine NAFLD screening — particularly when hepatotoxic systemic therapies are under consideration.

• Integration of weight-loss interventions alongside biologic therapy. GLP-1 receptor agonist therapy, caloric restriction, and bariatric surgery are recognized as complementary strategies to reduce psoriasis disease severity in obese patients. Emerging real-world evidence indicates that GLP-1 receptor agonist use is frequent among patients receiving biologic therapy, and tirzepatide's immunomodulatory properties have prompted investigation into potential therapeutic roles in inflammatory skin diseases, though current evidence remains limited to case reports and small studies. Optimal combination and sequencing strategies remain an active area of unmet need.

Taltz and Zepbound: Unveiling Biomarker Shifts in Psoriasis

Several biomarker and patient selection strategies have been investigated in trials of ixekizumab (Taltz). In the IXORA-R head-to-head Phase 4 study against guselkumab, transcriptomic profiling of lesional tissue revealed that ixekizumab-treated patients exhibited substantially greater numbers of differentially expressed genes as early as Week 1 (392 up-regulated, 696 down-regulated) compared to guselkumab-treated patients (0 up-regulated, 0 down-regulated), with the gap widening by Week 4 (ixekizumab: 1,882 up-regulated, 1,649 down-regulated; guselkumab: 318 up-regulated, 131 down-regulated). Differentially expressed genes involved in epidermal IL-17A and IL-36 responses were specifically correlated with PASI 100 response, providing a molecular basis for patient stratification. Separately, a population pharmacokinetic-pharmacodynamic model developed from a Phase 2 dose-finding study identified PASI 75 responder status at Week 12 as a significant covariate on EC50, suggesting that patients may have different levels of sensitivity to ixekizumab and that non-responders at lower doses might achieve response with doses yielding adequate exposures.

HLA-B27 status has also been evaluated as a patient selection and response-prediction biomarker for ixekizumab in axial spondyloarthritis across the COAST-V, COAST-W, and COAST-X trials. Among ixekizumab-treated patients with radiographic axSpA at Week 16, ASAS40 was achieved by 39.6% of HLA-B27-positive versus 29.3% of HLA-B27-negative patients, with the magnitude of benefit over placebo being 23.5% and 15.2%, respectively. Similar trends were observed at Week 52 and in non-radiographic axSpA, where HLA-B27-positive patients achieved ASAS40 at rates of 52.3% versus 32.0% for HLA-B27-negative patients. In the COAST-V MRI sub-analysis, subgroup analyses by sex, HLA-B27 status, and baseline bone marrow oedema score further demonstrated that decreases in sacroiliac joint erosion at Week 16 differed significantly between placebo and ixekizumab groups across these strata, reinforcing HLA-B27 and inflammatory imaging findings as clinically relevant patient selection variables.

For tirzepatide (Zepbound), a prospective pilot study investigated whether combinatorial fasting GLP-1 and GIP tertile profiles could predict the initial pharmacological weight-loss response. Among 90 treatment-naïve patients with severe obesity (mean BMI 42.5 ± 3.5 kg/m²), tirzepatide achieved optimal response (>15% body weight reduction) in profiles characterized by low GIP tertile regardless of GLP-1 level, while semaglutide achieved optimal response when GLP-1 was low and GIP was intermediate-to-high. Both drugs showed low response in the high GLP-1/high GIP profile. Mean weight loss in optimal-response groups was 18.2 ± 2.1% for tirzepatide and 16.8 ± 1.9% for semaglutide. Additionally, in the SUMMIT trial evaluating tirzepatide in HFpEF with obesity, diabetes status was a prespecified stratification variable; patients with type 2 diabetes lost 10.4% of body weight versus 12.9% in those without diabetes (P = 0.04), yet cardiovascular and functional outcomes — including reductions in paracardiac fat and left ventricular mass — were similar across both subgroups, suggesting that weight loss magnitude alone may not fully capture the clinical benefit of tirzepatide across patient phenotypes.

Shaping Future Combination Strategies for Psoriasis and Obesity

Emerging evidence highlights the intersection of obesity and psoriasis pathophysiology, with adipokines and pro-inflammatory cytokines from adipose tissue contributing to psoriasis disease pathogenesis. Combination approaches targeting both dermatologic and metabolic disease are gaining traction in clinical and real-world settings.

• Biologic therapy combined with weight-loss interventions: In obese patients with psoriasis, biologic therapy — particularly IL-17 and IL-23 inhibitors — is a mainstay of treatment, and combining these agents with interventions targeted at weight loss (including glucagon-like peptide-1 receptor agonist therapy, caloric restriction, and bariatric surgery) has been identified as a strategy to treat obesity and decrease psoriasis disease severity concurrently.

• IL-17 pathway inhibitors across BMI categories: Brodalumab, an IL-17 receptor inhibitor, demonstrated comparable efficacy across BMI categories in both clinical trial and real-world practice data, supporting its use in obese psoriasis patients as part of a broader management strategy that may include weight-loss co-interventions.

• Secukinumab combined with conventional systemic agents: Combination therapy of biologic agents with conventional systemic drugs — specifically secukinumab combined with methotrexate — has been proposed to optimize psoriasis treatment outcomes in unresponsive or partial-responsive severe psoriatic patients, with one reported case demonstrating significant clearance of psoriasis and reduction of arthritis approximately 24 weeks after starting the combined regimen.

• Deucravacitinib versus adalimumab in long-term extension trials: A matching-adjusted indirect comparison of the POETYK PSO-LTE and REVEAL extension trials found that adjusted week 112 PASI 75 response rates were significantly higher for deucravacitinib versus adalimumab (67.2% vs. 54.0%; mean difference [95% CI], 13.2 [4.0–22.5] percentage points), with deucravacitinib response rates remaining stable while adalimumab response rates declined in year 2 — a distinction relevant to obese patients where sustained efficacy is a clinical priority.

Redefining Psoriasis Treatment: The Power of Immune-Metabolic Synergy

The recent exploratory Phase IIIb results from Eli Lilly mark a pivotal moment in the treatment of moderate-to-severe plaque psoriasis, particularly for the significant patient population also grappling with obesity or overweight. For too long, therapeutic approaches have largely focused on managing the visible skin inflammation, often overlooking the profound metabolic dysfunction that frequently coexists and contributes to disease severity. This new data, demonstrating that combining Taltz (an IL-17A inhibitor) with Zepbound (a dual GLP-1/GIP receptor agonist) significantly alters a broader array of immune and metabolic biomarkers than Taltz alone, underscores a critical shift towards a more holistic, integrated treatment paradigm.

This synergy is not merely additive; it suggests a deeper, more comprehensive biological impact. The extensive shifts in protein and gene expression observed with dual therapy point to a fundamental rebalancing of both inflammatory and metabolic pathways. This could translate into not only superior skin clearance and substantial weight loss, as previously indicated, but also a more durable and profound reduction in the underlying systemic inflammation that drives both psoriasis and its cardiometabolic comorbidities.

However, this promising horizon comes with important considerations. While the individual safety profiles of Taltz and Zepbound are well-established, the long-term safety and tolerability of their combined use will require rigorous, extended evaluation. The potential for additive or synergistic adverse events, though not highlighted as a concern in the initial release, is a standard due diligence for any novel combination. Furthermore, the economic implications of a dual-therapy regimen involving two high-cost agents cannot be understated. Ensuring equitable access and managing the financial burden for patients and healthcare systems will be crucial. Finally, the complexity of a dual injectable regimen necessitates careful patient selection and robust support to ensure long-term adherence, which is paramount for sustained clinical benefits. This development heralds a new era where addressing the full spectrum of disease, including its metabolic underpinnings, becomes central to achieving optimal patient outcomes in chronic inflammatory conditions.